Soft Tissue Cancer
1447 clinical trials
351 cell line models
12 approved drugs
Soft Tissue Cancer
Molecular Synopsis
Drugs and clinical candidates

12 drugs have received FDA approval for Soft Tissue Cancer:

  • Dactinomycin
  • Doxorubicin Hydrochloride
  • Eribulin Mesylate
  • Imatinib Mesylate
  • Methotrexate Sodium

314 drugs have a clinical trial registered for Soft Tissue Cancer.

2883 compounds have been tested in Soft Tissue Cancer (2101 <= 500nM potency).

Sources:,, ChEMBL.

Clinical trials
There are 1447 clinical trials for Soft Tissue Cancer, 948 of which have one or more drug interventions, 499 with no drug intervention.
Cell line models

There are 351 Cell Line Models for Soft Tissue Cancer.

Source: COSMIC
Cell line models

Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from mesh condition terms to Soft Tissue Cancer:
  • Liposarcoma, Myxoid
  • Histiocytic Sarcoma
  • Leiomyosarcoma
  • Rhabdomyosarcoma
  • Glomus Tumor
The following terms have been mapped from to Soft Tissue Cancer:
  • AIDS-related Kaposi sarcoma
  • Liposarcoma (a type of soft tissue sarcoma) that cannot be removed by surgery or has metastasized. It is used in patients who have already been treated with anthracycline chemotherapy
  • Soft tissue sarcoma that cannot be cured with surgery or radiation therapy. It is used in adults with soft tissue sarcoma that has not already been treated with an anthracycline drug, such as doxorubicin
  • Osteosarcoma that has not spread to other parts of the body. It is used following surgery to remove the primary tumor
  • Soft tissue sarcoma that is advanced. It is used in patients who have already been treated with chemotherapy